Estrogen is a vital stimulant of breast cancer cells that expresses estrogen receptors (ER, especially ERα); therefore, antiestrogens and aromatase inhibitors have become pivotal as a therapeutic modality of ER-positive breast cancer patients [2,3]. The gene discussed is CYP19A1; the disease is breast carcinoma.